@Article{,
AUTHOR = {Peter J. Pommerville, Johan G. de Boer},
TITLE = {GnRH antagonists in the treatment of advanced prostate cancer},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {17},
YEAR = {2010},
NUMBER = {2},
PAGES = {5063--5070},
URL = {http://www.techscience.com/CJU/v17n2/62057},
ISSN = {1488-5581},
ABSTRACT = {Analogues of the gonadotropin releasing hormone 
(GnRH) inhibit the hypothalamic-pituitary-gonadal 
axis. This has provided treatment modalities for 
advanced and metastatic prostate cancer. The latest 
group of analogues, the GnRH antagonists, make 
promising treatments available that avoid the transient 
surge in testosterone that occurs with the use of GnRH 
agonists. Such surges may stimulate tumor growth, 
causing patients to experience new or worsening 
cancer symptoms and potential serious adverse effects, 
including increased bone pain, urinary retention, and 
spinal cord compression and consequently delay the 
therapeutic benefi ts of agonist therapy. Degarelix, an 
antagonist, recently approved in the United States and 
Europe, achieves faster, more profound and sustained 
testosterone suppression and with fewer adverse effects 
when compared with agonists and other antagonists. 
This review discusses and compares the compounds 
degarelix, abarelix, and cetrorelix.},
DOI = {}
}